Baricitinib in New-onset Type 1 Diabetes

Type 1 Diabetes Clinical Trial

— BANDIT  

Official title:

A Phase 2, Randomised, Placebo Controlled Study Investigating the Efficacy of Baricitinib in New Onset Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04774224
• Other study ID #: SVI-BARI-01
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 30, 2020
• Est. completion date: March 31, 2024

Study information

• Verified date: June 2023
• Source: St Vincent's Institute of Medical Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 1 diabetes (T1D) results from the killing of insulin-producing pancreatic beta cells by cells of the immune system. The study aims to slow the progressive, immune-mediated loss of insulin-producing beta cells that occurs after clinical presentation. The investigators have identified a pathway that is important for immune cells to kill beta cells, and a drug that will block this pathway and prevent beta cell death. This drug, baricitinib, is already in clinical use for rheumatoid arthritis, and is currently in clinical trials for other diseases, including childhood autoimmune diseases. It is hypothesized that baricitinib treatment for 48 weeks will preserve beta cell function in children and young adults with recently-diagnosed T1D. The trial aims to recruit 83 participants aged 10-30 years who have been recently diagnosed with T1D. Two thirds of the participants will be randomly assigned to receive baricitinib, one third will receive placebo. The trial will test if baricitinib can slow the progressive loss of insulin-producing beta cells in these patients. The primary objective is to determine if baricitinib can reduce the loss of meal-stimulated plasma C-peptide, a measure of beta-cell function. Maintaining endogenous insulin in recent-onset T1D improves glucose control and may lead to long-term improvements in glucose and lower rates of serious diabetes complications and death.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 91
• Est. completion date: March 31, 2024
• Est. primary completion date: January 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 30 Years

Eligibility

Inclusion Criteria:

1. Male or female aged between 10 and 30 years (inclusive) at screening;

2. Diagnosis of T1D according to ADA criteria within 100 days prior to starting study drug;

3. Islet autoantibody positivity (one or more of: GADA, IA-2A, IAA (assessed within one week of commencing insulin therapy), ZnT8A);

4. Stimulated (peak or 90 min) C-peptide >0.2 nM during a 2-hour MMTT at the screening visit; or random C-peptide result >0.3 nM during the screening period.

5. Participants of childbearing age who are sexually active must agree to use of effective birth control until the end of the study;

6. Be able to read, understand and give written informed consent;

7. Be willing to comply with intensive diabetes management.

Exclusion Criteria:

1. Use of immunosuppressive or immunomodulatory therapies other than inhaled or topical glucocorticoids;

2. Current or past history of deep vein thrombosis or pulmonary embolism;

3. Impaired renal function defined by estimated glomerular filtration rate (according to the CKD-EPI) of < 60 mL/min/1.73 m2;

4. LDL cholesterol >4mmol/l;

5. Elevated liver function tests at screening:

1. Aspartate aminotransferase 2x ULN

2. Alanine aminotransferase 2 x ULN;

6. Clinically significant abnormal laboratory parameters at screening including but not

limited to:

1. Hemoglobin < 8 g/L;

2. White blood cells <2500 cells/µl;

3. Lymphocyte count <750 cells/µl;

4. Platelets <50,000 cells/µl;

5. Neutrophils <1200cells/µL;

7. Known hypersensitivity to baricitinib;

8. Known malignancy with the exception of successfully treated non- metastatic basal cell and squamous cell carcinoma;

9. Pregnancy, a desire for pregnancy, breast feeding, or a desire to father a child during the study;

10. Patients with current or recent (within 12 weeks of screening) clinically significant comorbidity, including clinically serious viral, bacterial, fungal, or parasitic infection. Viral infections include HBV, HCV, EBV, HIV, recent herpes zoster and TB;

11. Treatment with any investigational product within 30 days or 5 half - lives (whichever is longer) prior to baseline visit, or concurrent participation in a clinical trial with an investigational product or device;

12. Experienced any of the following within 12 weeks of screening: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure;

13. Any serious medical condition within the previous 4 weeks which places the participant at an unacceptable risk if he or she were to participate in the study or confounds the ability to interpret data from the study, including, but not limited to, symptomatic cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine, haematological and neurological conditions or psychiatric illness/social situations that would limit compliance with study requirements;

14. Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study that, in the opinion of the investigator would pose an unacceptable risk to the participant;

15. History of chronic alcohol abuse or IV drug abuse or other illicit drug abuse within 2 years prior to screening.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Drug:
• Baricitinib
Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
• Placebo
Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.

Locations

Country	Name	City	State
Australia	St Vincent's Hospital Melbourne	Fitzroy	Victoria
Australia	Women's and Children's Hospital Adelaide	North Adelaide	South Australia
Australia	Royal Children's Hospital Melbourne	Parkville	Victoria
Australia	Royal Melbourne Hospital	Parkville	Victoria

Sponsors (3)

Lead Sponsor	Collaborator
St Vincent's Institute of Medical Research	Juvenile Diabetes Research Foundation, Juvenile Diabetes Research Foundation Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint of the study is the change from baseline of plasma C-peptide area under the curve (AUC) over 2 hours following a mixed meal.		Measured at 48 weeks post commencement of intervention.
Secondary	Change from baseline in plasma C-peptide AUC over 2 hours following a mixed meal.		Measured at weeks 12, 24, 72 and 96 post commencement of intervention.
Secondary	Change from baseline in mean daily insulin use over 7 consecutive days.		Measured during the 2 weeks prior to the assessment at weeks 12, 24, 48, 72 and 96 post commencement of intervention.
Secondary	Change from baseline in glycosylated haemoglobin (HbA1c) levels.		Measured at weeks 12, 24, 48, 72 and 96 post commencement of intervention.
Secondary	Number of participants with responder status. Responder status is defined as glycosylated haemoglobin (HbA1c) less than or equal to 6.5 percent and mean daily insulin use less than 0.5 international units per kilogram per day (IU/kg/day).		Measured at weeks 12, 24, 48, 72 and 96 post commencement of intervention.
Secondary	Change in estimated C-peptide (CPEST) from baseline. CPEST is calculated based on six variable routine measures: disease duration, BMI, insulin dose, HbA1c, fasting plasma C-peptide and fasting plasma glucose.		Measured at weeks 12, 24, 48, 72 and 96 post commencement of intervention.
Secondary	Continuous glucose monitoring (CGM).		Measured at baseline, 12, 24, 48 and 96 weeks post commencement of intervention.
Secondary	The composite outcome assessing both the frequency, and when relevant, the severity of all adverse events.		Adverse events will be monitored throughout the entire study duration at weeks 0, 2, 4, 8, 12, 16, 20, 24, 36, 48, 72 and 96.

External Links

•   Trial website